Castle Biosciences CSTL Stock
Castle Biosciences Price Chart
Castle Biosciences CSTL Financial and Trading Overview
| Castle Biosciences stock price | 34.2 USD |
| Previous Close | 32.93 USD |
| Open | 32.85 USD |
| Bid | 22.02 USD x 200 |
| Ask | 40.14 USD x 200 |
| Day's Range | 32.14 - 34.7 USD |
| 52 Week Range | 17.72 - 44.28 USD |
| Volume | 573.47K USD |
| Avg. Volume | 405.26K USD |
| Market Cap | 1.04B USD |
| Beta (5Y Monthly) | 0.974 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.64 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 44 USD |
CSTL Valuation Measures
| Enterprise Value | 814.64M USD |
| Trailing P/E | N/A |
| Forward P/E | -34.584232 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.9243143 |
| Price/Book (mrq) | 2.2197704 |
| Enterprise Value/Revenue | 2.28 |
| Enterprise Value/EBITDA | -49.324 |
Trading Information
Castle Biosciences Stock Price History
| Beta (5Y Monthly) | 0.974 |
| 52-Week Change | 66.26% |
| S&P500 52-Week Change | 18.67% |
| 52 Week High | 44.28 USD |
| 52 Week Low | 17.72 USD |
| 50-Day Moving Average | 25.83 USD |
| 200-Day Moving Average | 29.43 USD |
CSTL Share Statistics
| Avg. Volume (3 month) | 405.26K USD |
| Avg. Daily Volume (10-Days) | 394.73K USD |
| Shares Outstanding | 30.55M |
| Float | 27.08M |
| Short Ratio | 4.06 |
| % Held by Insiders | 2.47% |
| % Held by Institutions | 90.84% |
| Shares Short | 1.56M |
| Short % of Float | 5.23% |
| Short % of Shares Outstanding | 5.11% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -5.43% |
| Operating Margin (ttm) | -2.96% |
| Gross Margin | 77.25% |
| EBITDA Margin | -4.62% |
Management Effectiveness
| Return on Assets (ttm) | -1.35% |
| Return on Equity (ttm) | -4.19% |
Income Statement
| Revenue (ttm) | 357.28M USD |
| Revenue Per Share (ttm) | 12.04 USD |
| Quarterly Revenue Growth (yoy) | 20.10% |
| Gross Profit (ttm) | 276.03M USD |
| EBITDA | -16516000 USD |
| Net Income Avi to Common (ttm) | -19415000 USD |
| Diluted EPS (ttm) | -0.64 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 266.8M USD |
| Total Cash Per Share (mrq) | 8.73 USD |
| Total Debt (mrq) | 36.65M USD |
| Total Debt/Equity (mrq) | 7.8 USD |
| Current Ratio (mrq) | 6.036 |
| Book Value Per Share (mrq) | 15.407 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 42.63M USD |
| Levered Free Cash Flow (ttm) | -7256375 USD |
Profile of Castle Biosciences
| Country | United States |
| State | TX |
| City | Friendswood |
| Address | 1500 W. Parkwood Ave |
| ZIP | 77546 |
| Phone | 866 788 9007 |
| Website | https://castlebiosciences.com |
| Industry | Diagnostics & Research |
| Sector(s) | Healthcare |
| Full Time Employees | 1002 |
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Q&A For Castle Biosciences Stock
What is a current CSTL stock price?
Castle Biosciences CSTL stock price today per share is 34.2 USD.
How to purchase Castle Biosciences stock?
You can buy CSTL shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Castle Biosciences?
The stock symbol or ticker of Castle Biosciences is CSTL.
Which industry does the Castle Biosciences company belong to?
The Castle Biosciences industry is Diagnostics & Research.
How many shares does Castle Biosciences have in circulation?
The max supply of Castle Biosciences shares is 30.55M.
What is Castle Biosciences Price to Earnings Ratio (PE Ratio)?
Castle Biosciences PE Ratio is now.
What was Castle Biosciences earnings per share over the trailing 12 months (TTM)?
Castle Biosciences EPS is -0.64 USD over the trailing 12 months.
Which sector does the Castle Biosciences company belong to?
The Castle Biosciences sector is Healthcare.
Castle Biosciences CSTL included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26180.46 USD — |
+0.43
|
6.32B USD — | 26049.3 USD — | 26269.85 USD — | — - | 6.32B USD — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech Global Market Composite
NQGM
US
|
2339.66 USD — |
+1.23
|
— — | 2329.96 USD — | 2345.03 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7285.19 USD — |
+1.34
|
— — | 7209.03 USD — | 7347.6 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1367.82 USD — |
+1.36
|
— — | 1351.7 USD — | 1374.29 USD — | — - | — — |
- {{ link.label }} {{link}}
